N. Patkar

发表

Validation of diagnostic codes for subtrochanteric, diaphyseal, and atypical femoral fractures using administrative claims data.

M. Safford, K. Saag, P. Narongroeknawin, 2012, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Incidence and risk factors for Progressive Multifocal Leukoencephalopathy among patients with selected rheumatic diseases

J. Baddley, K. Saag, N. Patkar, 2012, Arthritis care & research.

Association of infections and tuberculosis with antitumor necrosis factor alpha therapy

K. Saag, N. Patkar, J. Curtis, 2008, Current opinion in rheumatology.

Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists.

M. Braun, K. Saag, N. Patkar, 2007, Rheumatology.

Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) Study

D. Solomon, J. Lewis, L. Herrinton, 2013, Annals of the rheumatic diseases.

Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists.

K. Saag, N. Patkar, J. Curtis, 2007, Arthritis and rheumatism.

Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs.

J. Allison, M. Braun, K. Saag, 2007, Arthritis and rheumatism.

Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster.

D. Solomon, J. Lewis, L. Herrinton, 2013, JAMA.

Biologics and heart failure in rheumatoid arthritis: are we any wiser?

M. Danila, K. Saag, N. Patkar, 2008, Current opinion in rheumatology.

Association of hyperlipidaemia , in fl ammation and serological status and coronary heart disease among patients with rheumatoid arthritis : data from the National Veterans Health Administration

J. Singh, S. Duvall, M. Safford, 2015 .

Brief report: incidence of selected opportunistic infections among children with juvenile idiopathic arthritis.

J. Baddley, K. Saag, N. Patkar, 2013, Arthritis and rheumatism.

K. Saag, A. Martini, R. Cron, 2011 .

Geographic Distribution of Endemic Fungal Infections among Older Persons, United States

J. Baddley, N. Patkar, J. Curtis, 2011, Emerging infectious diseases.

Validity of physician-reported hospitalized infections in a US arthritis registry.

D. Solomon, N. Patkar, Archana Jain, 2009, Rheumatology.

Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study.

Frederick W. Fraunfelder, D. Solomon, J. Lewis, 2013, American journal of ophthalmology.

2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

Jeffrey R Curtis, Maxime Dougados, Claire Bombardier, 2012, Arthritis care & research.

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

Jeffrey R Curtis, Kenneth G Saag, M. Hochberg, 2008, Arthritis and rheumatism.

Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients.

J. Allison, M. Saag, K. Saag, 2009, Journal of clinical epidemiology.

Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases.

Jeffrey R Curtis, Daniel H Solomon, Kenneth G Saag, 2011, JAMA.

Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists.

J. Allison, M. Saag, K. Saag, 2007, Arthritis and rheumatism.

2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features

Alberto Martini, K. Saag, A. Martini, 2011, Arthritis care & research.

Risk of Hospitalized Bacterial Infections Associated With Biologic Treatment Among US Veterans With Rheumatoid Arthritis

S. Duvall, M. Safford, J. Baddley, 2014, Arthritis care & research.

Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment.

R. Ouellet-Hellstrom, J. Lewis, J. Baddley, 2012, Arthritis and rheumatism.

Documented tuberculin skin testing among infliximab users following a multi‐modal risk communication interventions

J. Allison, L. Moreland, M. Braun, 2006, Pharmacoepidemiology and drug safety.

Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis

J. Singh, M. Safford, J. Baddley, 2011, Arthritis research & therapy.

Minor, Major, Low-Trauma, and High-Trauma Fractures: What Are the Subsequent Fracture Risks and How Do They Vary?

N. Patkar, E. Delzell, H. Yun, 2011, Current osteoporosis reports.

American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis

D. Furst, K. Saag, L. Caplan, 2010, Arthritis care & research.

Which fractures are most attributable to osteoporosis?

K. Saag, N. Patkar, J. Curtis, 2011, Journal of clinical epidemiology.

Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems

Jeffrey R Curtis, Kevin Haynes, Daniel H Solomon, 2011, Pharmacoepidemiology and drug safety.

Incidence of Selected Opportunistic Infections Among Children with Juvenile Idiopathic Arthritis

J. Baddley, K. Saag, N. Patkar, 2013 .

Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration

J. Singh, S. Duvall, M. Safford, 2015, Annals of the rheumatic diseases.

Recommendations for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis

M. Hochberg, D. Furst, M. Hannan, 1996 .

K. Saag, A. Martini, R. Cron, 2011, Arthritis care & research.

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

J. Allison, L. Moreland, K. Saag, 2008, Arthritis and rheumatism.

Design and challenges of a randomized clinical trial of medical expulsive therapy (tamsulosin) for urolithiasis in the emergency department.

S. Jackman, J. Hollander, J. Kusek, 2017, Contemporary clinical trials.